Welcome to our dedicated page for Axon Enterprise SEC filings (Ticker: AXON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Axon Enterprise, Inc. filings document operating results and corporate actions for a public safety technology company with Software & Services and Connected Devices activities. Form 8-K reports include shareholder letters on financial results and outlooks, product demand across TASER devices, Axon Body cameras, Axon Evidence, AI products, counter-drone offerings and real-time operations, as well as material-event disclosures tied to capital structure.
Proxy materials cover board composition, shareholder meeting matters, executive compensation and equity awards. Other 8-K and 8-K/A filings record director election updates and the redemption and settlement of 0.50% convertible senior notes due 2027, including the disclosure that no convertible notes remained outstanding after the redemptions and conversions.
Kant Eiso Hendricus Roland Leon reported acquisition or exercise transactions in this Form 4 filing.
AXON ENTERPRISE, INC. director Eiso Hendricus Roland Leon Kant reported a grant of 600 shares of Common Stock in the form of time-vested restricted stock units under the Axon Enterprise, Inc. Amended and Restated 2022 Stock Incentive Plan. These units are scheduled to vest in three equal installments beginning on July 8, 2027. Following this award, the reporting person holds 3,165 shares of Common Stock directly.
AXON ENTERPRISE, INC. director Kant Eiso Hendricus Roland Leon reported his initial holdings on a Form 3. He directly owns 2,565 shares of Common Stock. According to the footnote, these shares were acquired in open market transactions before his appointment as a director and before he became subject to Section 16 reporting.
MOHINDRA VIVEK reported acquisition or exercise transactions in this Form 4 filing.
Axon Enterprise, Inc. director Vivek Mohindra reported an equity compensation grant of 600 shares of common stock through time-vested restricted stock units under the Axon Enterprise, Inc. Amended and Restated 2022 Stock Incentive Plan. The award was granted at $0.00 per share and is scheduled to vest in three equal installments beginning on July 8, 2027, subject to the plan’s terms.
AXON ENTERPRISE, INC. director Vivek Mohindra filed an initial statement of beneficial ownership on Form 3. The filing reports no equity or derivative holdings in Axon securities by Mohindra as of this statement.
Axon Enterprise, Inc. appointed Vivek Mohindra and Eiso Kant to its Board of Directors effective July 8, 2026, each as an independent director with initial terms expiring at the 2027 annual meeting of stockholders. Mohindra will serve on the Audit Committee and Compensation Committee, and Kant will act as a non-voting observer of the Mergers & Acquisitions and Capital Structure Committee.
Each will receive an initial restricted stock unit award valued at $260,000, vesting in three equal annual installments, plus annual restricted stock unit awards of $260,000, vesting by the next annual meeting. Each will also receive annual cash compensation of $40,000, with Mohindra receiving additional annual cash retainers of $10,000 for Audit Committee service and $7,500 for Compensation Committee service. Axon has entered into indemnification agreements with both directors and states there are no related-party arrangements requiring disclosure.
Axon Enterprise CEO Patrick W. Smith reported selling 10,000 shares of common stock in open-market transactions. The trades occurred on July 7, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on May 12, 2025.
The sales were broken into multiple small trades, including executions at $628.2000 and $662.6950 per share. After these transactions, Smith directly holds 3,040,997 shares of Axon common stock, indicating he retains a very large equity position in the company.
AXON filed a Form 144 notice disclosing 10,000 shares of Common Stock to be sold by UBS Financial Services, Inc. as an option exercise dated 11/15/2021 for cash. The filing also lists recent sales by Patrick W. Smith: 20,000 shares sold on 06/04/2026 for $10,000,000 and 10,000 shares sold on 06/29/2026 for $5,000,018.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to the proposed sale of common stock connected to restricted shares originally granted 05/31/2020. The filing reports a sale by Julie Anne Cullivan of 446 shares on 06/01/2026 for $203,130.70. The record shows 479 restricted shares associated with the grant date 05/31/2020 and lists NASDAQ as the market.
Axon Enterprise CEO Patrick W. Smith reported an open-market sale of 10,000 shares of common stock at a weighted average price of $500.0018 per share on the reported transaction date. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 12, 2025.
Following this transaction, Smith directly holds 3,050,997 shares of Axon Enterprise common stock. The sale was carried out in multiple trades within a price range of $500.00 to $500.18, with the reported price reflecting the weighted average.
Axon Enterprise (AXON) notice: a Form 144 filing reports proposed sales of common stock by an issuer-related party and an individual. The filing lists 10,000 shares tied to an option exercise dated 11/15/2021 and a prior sale of 20,000 shares on 06/04/2026. The document names UBS Financial Services as broker and shows a transaction date of 06/29/2026.